BioSpace News Archive

The TULIP 2 trial was the second Phase III trial that assessed the safety and efficacy of anifrolumab as a treatment for adults with moderate-to-severe SLE.

Researchers may have found a new manner of treating a deadly form of prostate cancer by blocking a specific protein.

Promore Pharma AB today announced that the company was granted a patent in Japan for the usage of LL-37 for treating chronic wounds.

Kalos Therapeutics has engaged with The OCMX to assist in fund raising.

CrystalGenomics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CG-745, a clinical stage histone deacetylase (HDAC) inhibitor being developed for several hematologic malignancies and solid tumors, for the treatment of patients with pancreatic cancer.

The U.S. Food and Drug Administration is warning that some drugs that treat hepatitis C can, in rare cases, actually lead to the worsening of liver function or to live failure in patients with chronic hepatitis C.

The report, which is exaggerated or misinterpreted, appears to have been erroneous and triggered a short stock drop before the company and various analysts responded, calming investors.

The world is changing, and those prospering in STEM careers are leading the way. So why aren’t more girls jumping at the chance to get a foot in the field that offers incredible potential for growth and opportunity?

Company’s insulin-based Imotope™ IMCY-0098 shows excellent safety profile and promising clinical trends while eliciting immune responses supporting the proposed mode of action

Enterin Inc. announces the publication of its Phase 2a RASMET study.